Please try another search
For the six months ended 30 June 2020, Akorn, Inc. revenues decreased 6% to $325M. Net loss increased 68% to $325.4M. Revenues reflect Prescription Pharmaceuticals segment decrease of 7% to $283.7M, Foreign segment decrease of 30% to $4M. Higher net loss reflects Impairment of goodwill increase from $16M to $267.9M (expense), Interest Exp-Net of Capitalized Inte increase of 66% to $59.2M (expense).
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Revenue | 120.31 | 204.69 | 162.26 | 176.24 |
Gross Profit | 31.05 | 94.54 | 59.81 | 71.4 |
Operating Income | -61.69 | -246.92 | -43.98 | 8.77 |
Net Income | -68.66 | -256.73 | -80.66 | 47.67 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Assets | 1001.76 | 1032.28 | 1288.64 | 1398.36 |
Total Liabilities | 1080.46 | 1051.77 | 1054.35 | 1085.96 |
Total Equity | -78.7 | -19.49 | 234.29 | 312.41 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -71.06 | -61.43 | -36.92 | 4.79 |
Cash From Investing Activities | -18.56 | -11.14 | -30.4 | -23.61 |
Cash From Financing Activities | 27.94 | -0.09 | -12.93 | -0.66 |
Net Change in Cash | -61.74 | -72.7 | -80.19 | -19.45 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review